NASDAQ:FSTX F-star Therapeutics (FSTX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free FSTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$7.12▼$7.1250-Day Range$4.42▼$7.1252-Week Range$2.07▼$7.12VolumeN/AAverage Volume709,213 shsMarket Capitalization$156.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get F-star Therapeutics alerts: Email Address Ad Market Moving TrendsTop 5 AI Stocks to Buy for 20245 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In" About F-star Therapeutics Stock (NASDAQ:FSTX)F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.Read More Ad Market Moving TrendsTop 5 AI Stocks to Buy for 20245 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In" FSTX Stock News HeadlinesMay 10, 2024 | markets.businessinsider.comBuy Rating for Astria Therapeutics: Promising STAR-0215 Outpaces Competitors with Strategic Trials and Market PotentialMay 10, 2024 | markets.businessinsider.comAstria Therapeutics: Strong Buy Rating on Robust Finances and Promising Clinical TrialsMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Pliant Therapeutics (PLRX) and Crinetics Pharmaceuticals (CRNX)July 20, 2023 | dailymail.co.ukAdam22's porn star wife Lena The Plug ADMITS she enjoyed sex with other man MORE than husband'sJuly 12, 2023 | finance.yahoo.comA*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the USJuly 11, 2023 | dailymail.co.ukTwitch star Amouranth reveals she has been diagnosed with 'late stage ovarian failure' at AGE 29 - after 'shrugging off confusing mental and physical symptoms' for MONTHSJune 26, 2023 | startribune.comDouglas F. MayoJune 2, 2023 | finance.yahoo.comOchre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of DirectorsApril 24, 2023 | sfgate.comF. Murray Abraham apologizes after sexual misconduct allegationsMarch 8, 2023 | businesswire.cominvoX Pharma Completes Acquisition of F-star Therapeutics, Inc.March 7, 2023 | finanznachrichten.deF-star Therapeutics, Inc.: F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaMarch 7, 2023 | msn.comF-star Therapeutics surges as buyer Sino Biopharma gains CFIUS approvalMarch 7, 2023 | msn.comWhy F-Star Therapeutics Shares Are Moving HigherMarch 7, 2023 | marketwatch.comF-star Therapeutics Shares Rally After Cfius Clears Takeover >FSTXMarch 7, 2023 | finance.yahoo.comF-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaMarch 7, 2023 | msn.comF-Star Therapeutics Blasts Up as Merger Deal Goes ThroughMarch 7, 2023 | finance.yahoo.comF-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaMarch 7, 2023 | msn.comF-star Therapeutics surges on report sale to Sino Biopharma close to CFIUS approvalFebruary 25, 2023 | seekingalpha.comF-star Therapeutics jumps as it extends walk date with buyer to `finalize' CFIUS agreementFebruary 25, 2023 | morningstar.comF-star Therapeutics Inc Ordinary SharesFebruary 23, 2023 | msn.comF-star Therapeutics jumps as it extends walk date with buyer to `finalize" CFIUS agreementFebruary 22, 2023 | finance.yahoo.comWhile institutions own 48% of F-star Therapeutics, Inc. (NASDAQ:FSTX), retail investors are its largest shareholders with 49% ownershipFebruary 9, 2023 | msn.comF-star Therapeutics gains after deal termination date with buyer extended againFebruary 8, 2023 | msn.comF-star Therapeutics gains as buyer Sino Biopharma cancels Shanghai listingFebruary 1, 2023 | msn.comF-star Therapeutics up 18% as it extends end date of merger with invoX PharmaSee More Headlines Receive FSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FSTX CUSIPN/A CIK1566373 Webwww.f-star.com Phone441223497400Fax508-381-0347Employees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,280,000.00 Net MarginsN/A Pretax Margin-213.97% Return on Equity-57.08% Return on Assets-42.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$21.17 million Price / Sales7.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book1.51Miscellaneous Outstanding Shares21,980,000Free Float21,279,000Market Cap$156.50 million OptionableNot Optionable Beta0.85 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesEliot Richard ForsterPresident, Chief Executive Officer & DirectorDarlene M. Deptula-HicksChief Financial Officer, Treasurer & SecretaryLouis KayitalireChief Medical OfficerNeil BrewisChief Scientific OfficerJames SandyChief Development OfficerKey CompetitorsRepare TherapeuticsNASDAQ:RPTXCervoMedNASDAQ:CRVOProQR TherapeuticsNASDAQ:PRQRCytomX TherapeuticsNASDAQ:CTMXscPharmaceuticalsNASDAQ:SCPHView All Competitors FSTX Stock Analysis - Frequently Asked Questions How were F-star Therapeutics' earnings last quarter? F-star Therapeutics, Inc. (NASDAQ:FSTX) announced its earnings results on Wednesday, November, 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.06. The company had revenue of $0.75 million for the quarter, compared to the consensus estimate of $7.18 million. This page (NASDAQ:FSTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding F-star Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.